ATE532513T1 - Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von schädeltraumata - Google Patents

Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von schädeltraumata

Info

Publication number
ATE532513T1
ATE532513T1 AT08787960T AT08787960T ATE532513T1 AT E532513 T1 ATE532513 T1 AT E532513T1 AT 08787960 T AT08787960 T AT 08787960T AT 08787960 T AT08787960 T AT 08787960T AT E532513 T1 ATE532513 T1 AT E532513T1
Authority
AT
Austria
Prior art keywords
oxidopyridine
pyridi
cyclopropylmethoxy
carboxamide
dichloro
Prior art date
Application number
AT08787960T
Other languages
German (de)
English (en)
Inventor
Philippe Delay-Goyet
Corinne Perron
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE532513(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE532513T1 publication Critical patent/ATE532513T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT08787960T 2007-04-19 2008-04-16 Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von schädeltraumata ATE532513T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702852A FR2915099B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
PCT/FR2008/000531 WO2008145838A2 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Publications (1)

Publication Number Publication Date
ATE532513T1 true ATE532513T1 (de) 2011-11-15

Family

ID=38819821

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08787960T ATE532513T1 (de) 2007-04-19 2008-04-16 Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von schädeltraumata

Country Status (33)

Country Link
US (1) US9393236B2 (he)
EP (1) EP2146713B1 (he)
JP (1) JP5386476B2 (he)
KR (1) KR101460828B1 (he)
CN (1) CN101663036B (he)
AR (1) AR066105A1 (he)
AT (1) ATE532513T1 (he)
AU (1) AU2008257319B2 (he)
BR (1) BRPI0810423A2 (he)
CA (1) CA2684171C (he)
CL (1) CL2008001135A1 (he)
CO (1) CO6140028A2 (he)
CY (1) CY1112282T1 (he)
DK (1) DK2146713T3 (he)
EA (1) EA015503B1 (he)
ES (1) ES2376023T3 (he)
FR (1) FR2915099B1 (he)
HR (1) HRP20120130T1 (he)
IL (1) IL201447A (he)
JO (1) JO2861B1 (he)
MA (1) MA31368B1 (he)
ME (2) ME00938B (he)
MX (1) MX2009011214A (he)
MY (1) MY147207A (he)
NZ (1) NZ580484A (he)
PA (1) PA8776701A1 (he)
PL (1) PL2146713T3 (he)
PT (1) PT2146713E (he)
RS (1) RS52130B (he)
SI (1) SI2146713T1 (he)
TW (1) TWI423800B (he)
UY (1) UY31034A1 (he)
WO (1) WO2008145838A2 (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2621894C2 (ru) * 2012-11-28 2017-06-08 Санофи Способ получения новых кристаллических форм-4(циклопропилметокси)-n-(3, 5-дихлор-1-оксидопиридин-4-ил)-5-метоксипиридин-2-карбоксамида и его кристаллические формы
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1273326A (en) * 1917-08-22 1918-07-23 George H Bugenhagen Transmission mechanism.
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
EP0711282B1 (en) * 1993-07-28 2002-06-05 Aventis Pharma Limited Compounds as pde iv and tnf inhibitors
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) * 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
WO2000075116A2 (en) * 1999-06-07 2000-12-14 Warner-Lambert Company Tricyclic analgesics
EP1244649B1 (en) * 1999-12-23 2005-03-02 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
JP2007525482A (ja) 2003-10-07 2007-09-06 レノビス， インコーポレイテッド イオンチャネルリガンドとしてのアミド化合物およびその使用
CA2611562A1 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury
FR2915098B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Also Published As

Publication number Publication date
MY147207A (en) 2012-11-14
ME00938B (me) 2012-06-20
CN101663036B (zh) 2012-06-20
CA2684171C (fr) 2015-12-01
JP2010524903A (ja) 2010-07-22
KR20090130058A (ko) 2009-12-17
AU2008257319B2 (en) 2013-07-25
PT2146713E (pt) 2012-02-07
CY1112282T1 (el) 2015-12-09
MX2009011214A (es) 2009-11-02
CO6140028A2 (es) 2010-03-19
WO2008145838A2 (fr) 2008-12-04
CA2684171A1 (fr) 2008-12-04
BRPI0810423A2 (pt) 2014-10-14
AR066105A1 (es) 2009-07-22
TWI423800B (zh) 2014-01-21
EA015503B1 (ru) 2011-08-30
MA31368B1 (fr) 2010-05-03
SI2146713T1 (sl) 2012-03-30
US20100130553A1 (en) 2010-05-27
ES2376023T3 (es) 2012-03-08
RS52130B (sr) 2012-08-31
ME01273B (me) 2013-06-20
EP2146713A2 (fr) 2010-01-27
FR2915099A1 (fr) 2008-10-24
EA200970968A1 (ru) 2010-02-26
HRP20120130T1 (hr) 2012-03-31
UY31034A1 (es) 2008-11-28
JP5386476B2 (ja) 2014-01-15
JO2861B1 (en) 2015-03-15
HK1141724A1 (en) 2010-11-19
IL201447A0 (en) 2010-05-31
PL2146713T3 (pl) 2012-04-30
CN101663036A (zh) 2010-03-03
TW200914009A (en) 2009-04-01
PA8776701A1 (es) 2008-11-19
EP2146713B1 (fr) 2011-11-09
CL2008001135A1 (es) 2009-01-16
NZ580484A (en) 2011-06-30
WO2008145838A3 (fr) 2009-03-26
FR2915099B1 (fr) 2009-06-05
US9393236B2 (en) 2016-07-19
KR101460828B1 (ko) 2014-11-11
AU2008257319A1 (en) 2008-12-04
DK2146713T3 (da) 2012-03-05
IL201447A (he) 2013-07-31

Similar Documents

Publication Publication Date Title
EP3861968C0 (en) DEVICES FOR THE TREATMENT OF SLEEP APNEA
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EP1755661A4 (en) USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
EP1765391A4 (en) BACTERIAL COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3871639C0 (en) GASTRO-SOPHAGEAL REFLUX TREATMENT DEVICE
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
EP1758597A4 (en) USE OF MEDICINAL COMBINATIONS FOR TREATING INSULIN RESISTANCE
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES
DE602008002843D1 (de) Neue antimikrobielle verbindungen, ihre synthese und ihre verwendung zur behandlung von säugetierinfektionen
DE602007010303D1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EP2249765A4 (en) DAPSONE TO TREAT THE ROSACEA
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ATE472324T1 (de) Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
EP1863520A4 (en) USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER
ATE516805T1 (de) Medikament zur behandlung von endometriose
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
ATE503481T1 (de) Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von rückenmarksverletzungen